Shionogi and Sciele Announce Receipt of United States Antitrust Clearance
19 Septiembre 2008 - 5:00AM
Business Wire
Shionogi & Co., Ltd. (�Shionogi�) and Sciele Pharma, Inc.
(�Sciele�) (NASDAQ: SCRX) announced today that the waiting period
under the Hart Scott Rodino Antitrust Improvements Act of 1976 with
respect to Shionogi's indirect wholly owned subsidiary�s cash
tender offer for all outstanding shares of common stock of Sciele
at a price of $31.00 per share expired at 11:59 P.M., New York City
time, on September 18, 2008. Accordingly, the condition to the
tender offer with respect to the antitrust and competition laws of
the United States has been satisfied. The tender offer is currently
scheduled to expire at 12:00 Midnight, New York City time, on
Friday, October 3, 2008. The tender offer is being made pursuant to
the previously announced agreement of merger among Shionogi, its
indirect wholly owned subsidiary, and Sciele. Additional
Information and Where to Find It THIS ANNOUNCEMENT IS FOR
INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO
PURCHASE OR A SOLICITATION OF AN OFFER TO SELL SCIELE�S COMMON
STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER
STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER
OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) THAT WAS
FILED BY TALL BRIDGE, INC. WITH THE SECURITIES AND EXCHANGE
COMMISSION (SEC) ON SEPTEMBER 8, 2008. THESE MATERIALS, AS THEY MAY
BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION,
INCLUDING THE TERMS AND CONDITIONS OF THE OFFER, THAT SHOULD BE
READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE
TENDER OFFER. INVESTORS AND STOCKHOLDERS CAN OBTAIN A FREE COPY OF
THESE MATERIALS AND OTHER DOCUMENTS FILED BY TALL BRIDGE, INC. WITH
THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV. THE
TENDER OFFER MATERIALS MAY ALSO BE OBTAINED FOR FREE BY CONTACTING
THE INFORMATION AGENT FOR THE TENDER OFFER, GEORGESON, AT
1-212-440-9800 FOR BANKS AND BROKERS AND 1-800-334-9586 FOR
SHAREHOLDERS AND ALL OTHERS, OR BY WRITING TO 199 WATER STREET,
26TH FLOOR, NEW YORK, NY 10038. About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major research-driven Japanese
pharmaceutical manufacturer. The company�s primary businesses are
research and development, manufacturing, marketing, and import and
export sales of pharmaceuticals and diagnostics. Shionogi follows a
basic policy of continually providing the superior medicines
essential to people�s health. For more details, please visit
www.shionogi.co.jp. About Sciele Pharma, Inc. Sciele Pharma, Inc.
is a pharmaceutical company specializing in sales, marketing and
development of branded prescription products focused on the
therapeutic areas of Cardiovascular, Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular and Diabetes products
treat patients with high cholesterol, hypertension, high
triglycerides, unstable angina and Type 2 diabetes; its Women's
Health products are designed to improve the health and well-being
of women and mothers and their babies; and its Pediatrics products
treat allergies, asthma, coughs and colds, and attention deficit
and hyperactivity disorder (ADHD). The Company was founded in 1992
and is headquartered in Atlanta, Georgia. The Company employs more
than 1,000 people. The Company's success is based on placing the
needs of patients first, improving health and quality of life, and
implementing its business platform � an Entrepreneurial Spirit,
Innovation, Execution Excellence, Simplicity, and Teamwork. For
more information on Sciele, please visit www.sciele.com.
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024